Given its mechanism of action, the clinical data already demonstrated in multiple clinical studies, and the results of within-class competitors, I believe that GSK's product will demonstrate high ...

The drug is positioned as a follow-up product to GSK’s blockbuster Advair/Seretide, but the company is now facing generic competition against its older drug, plus new rivals from the likes of ...

The published belrestotug/dostarlimab data is still too immature to prove the combination’s capability to disrupt the NSCLC ...

Roula Khalaf, Editor of the FT, selects her favourite stories in this weekly newsletter. GSK has pushed back on US claims it is holding back competition among drugmakers with “junk patents ...

PZ Cussons has decided to leave Nigeria, citing naira's devaluation as the reason after GSK, Sanofi and other multinationals ...

GSK plc (NYSE:GSK) released the headline results of the MATINEE Phase 3 trial evaluating Nucala (mepolizumab), a monoclonal ...

GSK’s twice-yearly depemokimab reduced asthma attacks by half and cut clinic visits by nearly three-quarters, positioning it ...

Everything we covered on WTR over the past seven days, and all you need to know from the world of trademarks to set yourself up for the start of another busy week.

GSK’s (LSE: GSK) share price is 9% down from its 15 May 12-month traded high of £18.19. This compounds the stock’s already extreme undervaluation against its competitors apparent to me beforehand.

Analyst Graham Parry from Bank of America Securities maintained a Sell rating on GlaxoSmithKline (GSK – Research Report) and keeping the ...

First Opinion is STAT’s platform for interesting, illuminating, and provocative articles about the life sciences writ large, ...

GSK’s GSK phase III study evaluating its blockbuster drug Nucala (mepolizumab), an anti-IL5 biologic, for treating chronic ...